Parietal epithelial cell dysfunction in crescentic glomerulonephritis.
Wong MN, Tharaux PL, Grahammer F, Puelles VG.
Cell Tissue Res. 2021 Aug;385(2):345-354. doi: 10.1007/s00441-021-03513-9. Epub 2021 Aug 28.
Crescentic glomerulonephritis associated with syphilis: a case report and review of the literature.
Kaiga A, Sato Y, Arakawa H, Rai T, Tojo A.
J Med Case Rep. 2023 Dec 22;17(1):549. doi: 10.1186/s13256-023-04293-2.
Update on crescentic glomerulonephritis.
Hénique C, Papista C, Guyonnet L, Lenoir O, Tharaux PL.
Semin Immunopathol. 2014 Jul;36(4):479-90. doi: 10.1007/s00281-014-0435-7. Epub 2014 Jun 20.
Pauci-Immune Crescentic Glomerulonephritis: An ANCA-Associated Vasculitis.
Syed R, Rehman A, Valecha G, El-Sayegh S.
Biomed Res Int. 2015;2015:402826. doi: 10.1155/2015/402826. Epub 2015 Nov 25.
Novel therapeutic perspectives for crescentic glomerulonephritis through targeting parietal epithelial cell activation and proliferation.
Huang Y, Zhao X, Zhang Q, Yang X, Hou G, Peng C, Jia M, Zhou L, Yamamoto T, Zheng J.
Expert Opin Ther Targets. 2023 Jan;27(1):55-69. doi: 10.1080/14728222.2023.2177534. Epub 2023 Feb 16.
Rapidly progressive crescentic glomerulonephritis: Early treatment is a must.
Moroni G, Ponticelli C.
Autoimmun Rev. 2014 Jul;13(7):723-9. doi: 10.1016/j.autrev.2014.02.007. Epub 2014 Mar 19.
Crescentic glomerulonephritis--a manifestation of a nephritogenic Th1 response?
Kitching AR, Holdsworth SR, Tipping PG.
Histol Histopathol. 2000 Jul;15(3):993-1003. doi: 10.14670/HH-15.993.
[Crescentic glomerulonephritis].
Ueno M, Arakawa M.
Nihon Rinsho. 1994 Aug;52(8):2082-8.
Management of crescentic glomerulonephritis: what are the recent advances?
Li X, Chen N.
Contrib Nephrol. 2013;181:229-39. doi: 10.1159/000348479. Epub 2013 May 8.
Predictors of renal outcomes in crescentic and mixed class of ANCA-associated glomerulonephritis.
You X, Zhang J, Ding X, Zhang J, Zhou Q, Lu G.
Clin Nephrol. 2021 Feb;95(2):81-86. doi: 10.5414/CN110221.
